BeiGene (BGNE) said late Thursday it has signed a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology for its experimental cancer therapy, SYH2039.
Under the terms of the deal, the company said it has an exclusive worldwide license to develop, manufacture and commercialize SYH2039.
CSPC will receive $150 million in upfront, time-based payments, potential milestone payments and tiered royalties.
The company said its experimental drug, BGB-58067, is expected to enter clinical trials by the end of the year and aims to avoid the hematological toxicity associated with first-generation PRMT5 inhibitors.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。